Product
Help
Pricing
About
Jobs
Log in
Get started
Keyword
Add to collection
AZD5991
Description:
An experimental macrocyclic small-molecule inhibitor of myeloid cell leukemia 1, investigated as a treatment for hematologic cancers.
Primary topic:
Cell death mechanisms and regulation (39%)
Related topics:
Cell death mechanisms and regulation (39%),
Acute Myeloid Leukemia Research (19%)
OpenAlex ID:
keywords/azd5991
Discovery of Mcl-1-specific inhibitor AZD5991 and preclinical activity in multiple myeloma and acute myeloid leukemia
2018
·
Adriana E. Tron
, Matthew A. Belmonte
, et al.
·
Nature Communications
·
537
PDF
Targeting MCL-1 in hematologic malignancies: Rationale and progress
2020
·
Andrew H. Wei
, Andrew W. Roberts
, et al.
·
Blood Reviews
·
229
PDF
Integrated analysis of patient samples identifies biomarkers for venetoclax efficacy and combination strategies in acute myeloid leukemia
2020
·
Haijiao Zhang
, Yusuke Nakauchi
, et al.
·
Nature Cancer
·
220
Targeting MCL-1 dysregulates cell metabolism and leukemia-stroma interactions and re-sensitizes acute myeloid leukemia to BCL-2 inhibition
2020
·
Bing Z. Carter
, Po Yee Mak
, et al.
·
Haematologica
·
138
PDF
Targeting melanoma’s MCL1 bias unleashes the apoptotic potential of BRAF and ERK1/2 pathway inhibitors
2019
·
Matthew J. Sale
, Emma Minihane
, et al.
·
Nature Communications
·
80
PDF
Biomarker-driven strategy for MCL1 inhibition in T-cell lymphomas
2018
·
Raphael Koch
, Amanda L. Christie
, et al.
·
Blood
·
69
PDF
A Phase 1 First-in-Human Study of the MCL-1 Inhibitor AZD5991 in Patients with Relapsed/Refractory Hematologic Malignancies
2024
·
Pinkal Desai
, Sagar Lonial
, et al.
·
Clinical Cancer Research
·
68
PDF
Pharmacologic Targeting of Mcl-1 Induces Mitochondrial Dysfunction and Apoptosis in B-Cell Lymphoma Cells in a TP53- and BAX- Dependent Manner
2021
·
Tingting Liu
, Vi Lam
, et al.
·
Clinical Cancer Research
·
60
PDF
Free Ligand 1D NMR Conformational Signatures To Enhance Structure Based Drug Design of a Mcl-1 Inhibitor (AZD5991) and Other Synthetic Macrocycles
2019
·
Amber Y. S. Balazs
, Rodrigo J. Carbajo
, et al.
·
Journal of Medicinal Chemistry
·
44
Discovery of β-carboline copper(II) complexes as Mcl-1 inhibitor and in vitro and in vivo activity in cancer models
2019
·
Xing Lu
, Yan-Cheng Liu
, et al.
·
European Journal of Medicinal Chemistry
·
35
Mechanisms of MCL-1 Protein Stability Induced by MCL-1 Antagonists in B-Cell Malignancies
2022
·
Shady I. Tantawy
, Aloke Sarkar
, et al.
·
Clinical Cancer Research
·
33
PDF
c-Myc plays a critical role in the antileukemic activity of the Mcl-1-selective inhibitor AZD5991 in acute myeloid leukemia
2022
·
Shuang Liu
, Xinan Qiao
, et al.
·
APOPTOSIS
·
30
Impact of the physical-chemical properties of poly(lactic acid)–poly(ethylene glycol) polymeric nanoparticles on biodistribution
2023
·
Mark J. Jackman
, Weimin Li
, et al.
·
Journal of Controlled Release
·
27
PDF
Abstract DDT01-02: AZD5991: A potent and selective macrocyclic inhibitor of Mcl-1 for treatment of hematologic cancers
2017
·
Alexander W. Hird
, J. Paul Secrist
, et al.
·
Cancer Research
·
26
Screening of predicted synergistic multi-target therapies in glioblastoma identifies new treatment strategies
2023
·
Megan Houweling
, Anna Giczewska
, et al.
·
Neuro-Oncology Advances
·
22
PDF
Design of rigid protein–protein interaction inhibitors enables targeting of undruggable Mcl-1
2023
·
David Hargreaves
, Rodrigo J. Carbajo
, et al.
·
Proceedings of the National Academy of Sciences
·
15
Cotargeting of Bcl-2 and Mcl-1 shows promising antileukemic activity against AML cells including those with acquired cytarabine resistance
2021
·
Fangbing Liu
, Qiushi Zhao
, et al.
·
Experimental Hematology
·
15
Irreversible JNK blockade overcomes PD-L1-mediated resistance to chemotherapy in colorectal cancer
2021
·
Lei Sun
, Árpád V. Patai
, et al.
·
Oncogene
·
15
Potentiation of apoptosis in drug-resistant mantle cell lymphoma cells by MCL-1 inhibitor involves downregulation of inhibitor of apoptosis proteins
2023
·
Yijing Li
, Heng-Huan Lee
, et al.
·
Cell Death and Disease
·
12
PDF
Targeting MCL‐1 to Overcome Therapeutic Resistance and Improve Cancer Mortality
2025
·
Md Mohiuddin
·
Health Science Reports
·
11
Peptide and Small Molecule Inhibitors Targeting Myeloid Cell Leukemia 1 (Mcl-1) as Novel Antitumor Agents
2020
·
Xing Lu
, Hong Liang
, et al.
·
Current Molecular Medicine
·
11
Mcl-1 mediates intrinsic resistance to RAF inhibitors in mutant BRAF papillary thyroid carcinoma
2024
·
Maria R. Cavallo
, Jacob C. Yo
, et al.
·
Cell Death Discovery
·
10
PDF
Inhibition of Mcl-1 Synergistically Enhances the Antileukemic Activity of Gilteritinib and MRX-2843 in Preclinical Models of FLT3-Mutated Acute Myeloid Leukemia
2022
·
Shuangshuang Wu
, Holly Edwards
, et al.
·
Cells
·
10
PDF
Involvement of MCL1, c-myc, and cyclin D2 protein degradation in ponatinib-induced cytotoxicity against T315I(+) Ph+leukemia cells
2020
·
Chisato Inoue
, Sayaka Sobue
, et al.
·
Biochemical and Biophysical Research Communications
·
10
Preclinical Activity of Novel MCL1 Inhibitor AZD5991 in Multiple Myeloma
2018
·
Shannon M Matulis
, Vikas A. Gupta
, et al.
·
Blood
·
10
Show more works
View as search
Works count:
121
Citation count:
1,839
Year
Topic
Type